Trial Profile
A Phase 2 Study of Sipuleucel-T With or Without Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-Metastatic Castrate-Resistant Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary) ; Sipuleucel-T
- Indications Adenocarcinoma; Bone metastases; Prostate cancer
- Focus Pharmacodynamics
- 15 Jun 2021 Status changed from active, no longer recruiting to completed.
- 05 Mar 2021 Planned End Date changed from 1 May 2021 to 1 Jun 2021.
- 05 Mar 2021 Planned primary completion date changed from 1 Feb 2021 to 1 Jun 2021.